Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 06 2023
Historique:
received: 28 02 2023
accepted: 07 06 2023
medline: 19 6 2023
pubmed: 18 6 2023
entrez: 17 6 2023
Statut: epublish

Résumé

Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising target for treatment of inflammatory disease. Here, we describe the identification of tozorakimab (MEDI3506), a potent, human anti-IL-33 monoclonal antibody, which can inhibit reduced IL-33 (IL-33

Identifiants

pubmed: 37330528
doi: 10.1038/s41598-023-36642-y
pii: 10.1038/s41598-023-36642-y
pmc: PMC10276851
doi:

Substances chimiques

Interleukin-1 Receptor-Like 1 Protein 0
Interleukin-33 0
Cytokines 0
ErbB Receptors EC 2.7.10.1
EGFR protein, human EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9825

Informations de copyright

© 2023. The Author(s).

Références

J Inflamm Res. 2021 Aug 11;14:3823-3835
pubmed: 34408465
Immunity. 2020 May 19;52(5):782-793.e5
pubmed: 32272082
Immunity. 2015 Mar 17;42(3):566-79
pubmed: 25786179
Nat Biotechnol. 1996 Mar;14(3):309-14
pubmed: 9630891
Nat Genet. 2015 May;47(5):448-52
pubmed: 25807282
Sci Rep. 2018 Feb 20;8(1):3363
pubmed: 29463838
N Engl J Med. 2021 Oct 28;385(18):1656-1668
pubmed: 34706171
Cytokine. 2008 Jun;42(3):358-64
pubmed: 18450470
J Mol Biol. 2004 Oct 22;343(3):685-701
pubmed: 15465055
Cytokine. 2016 Jul;83:33-40
pubmed: 27031441
J Mol Biol. 2017 Jan 20;429(2):208-219
pubmed: 27956146
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27307-27318
pubmed: 33067389
Int Immunol. 2008 Aug;20(8):1019-30
pubmed: 18550585
J Cell Commun Signal. 2018 Sep;12(3):615-624
pubmed: 29705949
Immunol Rev. 2017 Jul;278(1):173-184
pubmed: 28658560
Structure. 2009 Oct 14;17(10):1398-410
pubmed: 19836339
Lancet Rheumatol. 2020 Dec;2(12):e779-e790
pubmed: 33073244
J Immunol. 2011 Apr 1;186(7):4375-87
pubmed: 21357533
MAbs. 2014 Jan-Feb;6(1):236-45
pubmed: 24256948
PLoS One. 2017 Jun 14;12(6):e0178939
pubmed: 28614418
Am J Cardiol. 2015 Apr 2;115(7 Suppl):8B-21B
pubmed: 25697919
Cell Physiol Biochem. 2018;49(1):349-358
pubmed: 30138941
Methods. 2015 Apr;76:116-123
pubmed: 25461813
Nat Genet. 2015 May;47(5):435-44
pubmed: 25807286
PLoS Genet. 2017 Mar 8;13(3):e1006659
pubmed: 28273074
Front Immunol. 2017 Apr 24;8:475
pubmed: 28484466
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14918-23
pubmed: 23980170
Front Immunol. 2012 Apr 19;3:82
pubmed: 22566963
Lancet Respir Med. 2021 Nov;9(11):1288-1298
pubmed: 34302758
Annu Rev Immunol. 2022 Apr 26;40:15-43
pubmed: 34985928
MAbs. 2011 Jan-Feb;3(1):49-60
pubmed: 21048425
Clin Transl Immunology. 2020 Jun 17;9(6):e1146
pubmed: 32566227
MAbs. 2015;7(1):129-37
pubmed: 25523454
J Biol Chem. 2022 Feb;298(2):101533
pubmed: 34973336
Anal Biochem. 2016 Sep 1;508:78-96
pubmed: 27365220
Lancet Respir Med. 2022 May;10(5):469-477
pubmed: 35339234
Assay Drug Dev Technol. 2004 Dec;2(6):647-57
pubmed: 15674023
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8765-70
pubmed: 27432971
Front Immunol. 2019 Jun 20;10:1412
pubmed: 31281320
J Mol Biol. 2011 Aug 26;411(4):791-807
pubmed: 21723291
J Allergy Clin Immunol. 2021 Sep;148(3):790-798
pubmed: 33872652
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10701-5
pubmed: 10984501
Mol Med. 2021 Mar 26;27(1):29
pubmed: 33771098
Curr Opin Struct Biol. 2013 Dec;23(6):887-93
pubmed: 23850142
J Autoimmun. 2014 Dec;55:33-41
pubmed: 24786898
Immunity. 2015 Jun 16;42(6):991-1004
pubmed: 26084020
FEBS Lett. 1989 Dec 4;258(2):301-4
pubmed: 2532153
Immunity. 2015 Jun 16;42(6):1005-19
pubmed: 26084021
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):282-7
pubmed: 17185418
Respir Res. 2020 Sep 22;21(1):245
pubmed: 32962703
J Allergy Clin Immunol. 2019 Jul;144(1):204-215
pubmed: 30876911
Respir Med. 2018 Jul;140:50-56
pubmed: 29957280
Medicina (Kaunas). 2019 Feb 14;55(2):
pubmed: 30769901
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
J Allergy Clin Immunol. 2008 Jun;121(6):1484-90
pubmed: 18539196
Eur Cytokine Netw. 2012 Oct-Dec;23(4):120-7
pubmed: 23306193
J Clin Invest. 2013 Sep;123(9):3967-82
pubmed: 23945235
Protein Eng Des Sel. 2009 Mar;22(3):159-68
pubmed: 18974080
Am J Cardiol. 2015 Apr 2;115(7 Suppl):3B-7B
pubmed: 25665766
Nat Commun. 2021 May 14;12(1):2795
pubmed: 33990604
Nat Commun. 2015 Sep 14;6:8327
pubmed: 26365875
Eur J Immunol. 2009 Apr;39(4):1046-55
pubmed: 19266498
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1004-13
pubmed: 16038881

Auteurs

Elizabeth England (E)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

D Gareth Rees (DG)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Ian Christopher Scott (IC)

Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Sara Carmen (S)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Denice T Y Chan (DTY)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Catherine E Chaillan Huntington (CE)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Kirsty F Houslay (KF)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Teodor Erngren (T)

Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Mark Penney (M)

Early Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.

Jayesh B Majithiya (JB)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Laura Rapley (L)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Dorothy A Sims (DA)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

Claire Hollins (C)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Elizabeth C Hinchy (EC)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Martin D Strain (MD)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Benjamin P Kemp (BP)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Dominic J Corkill (DJ)

Bioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Richard D May (RD)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Katherine A Vousden (KA)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Robin J Butler (RJ)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Tomas Mustelin (T)

Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA.

Tristan J Vaughan (TJ)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

David C Lowe (DC)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

Caroline Colley (C)

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

E Suzanne Cohen (ES)

Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. suzanne.cohen@astrazeneca.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH